文献速递心脑血管急症

无客观检查规则验证及与HEART路径的比较

Validation of the No Objective Testing Rule and Comparison to the HEART Pathway.
PubMed 文献 · Acad Emerg Med · 2017-08-08
一句话结论在美国急诊胸痛患者中,NOTR与HEART路径对30天MACE均100%敏感,但HEART路径能识别更多适合早期出院的低危患者。

本研究为HEART路径随机对照试验的二次分析,纳入282例美国急诊急性胸痛患者,按NOTR分类为低危或高危,计算30天主要不良心脏事件(MACE)敏感性,并在HEART路径组(n=141)中比较NOTR与HEART路径的性能。30天MACE发生22/282(7.8%),包括0例死亡、16/282(5.6%)心肌梗死和6/282(2.1%)无心肌梗死的冠状动脉血运重建。NOTR对MACE敏感性为100%(95%CI 84.6%-100%),将78/282例(27.7%,95%CI 22.5%-33.3%)识别为低危。在HEART路径组中,NOTR和HEART路径均将所有MACE患者识别为高危;与NOTR相比,HEART路径能将27例无MACE患者正确重分类为低危,净重分类改善(NRI)为20.8%(95%CI 11.3%-30.2%)。

要点

  • 在282例美国急诊胸痛患者中,30天MACE发生率为7.8%(22/282),包括0例死亡、5.6%(16/282)心肌梗死和2.1%(6/282)无心肌梗死的血运重建。
  • NOTR对30天MACE的敏感性为100%(95%CI 84.6%-100%),将27.7%(78/282,95%CI 22.5%-33.3%)的患者识别为低危。
  • 在HEART路径组(n=141)中,NOTR和HEART路径均将所有MACE患者识别为高危。
  • 与NOTR相比,HEART路径能将27例无MACE患者正确重分类为低危,NRI为20.8%(95%CI 11.3%-30.2%)。
  • HEART路径识别的适合早期出院患者多于NOTR,但两者对MACE的敏感性均为100%。

适用人群与场景

  • 美国急诊科急性胸痛患者,纳入HEART路径随机对照试验的282例参与者。

研究设计与关键结果

  • 研究类型:HEART路径随机对照试验的二次分析,样本量282例,人群为美国急诊急性胸痛患者。
  • 30天MACE发生22/282(7.8%),包括0例死亡、16/282(5.6%)心肌梗死和6/282(2.1%)无心肌梗死的冠状动脉血运重建。
  • NOTR对MACE敏感性为100%(95%CI 84.6%-100%),识别低危78/282例(27.7%,95%CI 22.5%-33.3%)。
  • 在HEART路径组(n=141)中,NOTR和HEART路径均将所有MACE患者识别为高危。
  • 与NOTR相比,HEART路径将27例无MACE患者正确重分类为低危,NRI为20.8%(95%CI 11.3%-30.2%)。

证据类型、等级与局限

  • 证据类型:随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在美国急诊胸痛队列中,NOTR和HEART路径对30天MACE均100%敏感,但HEART路径识别出更多适合早期出院的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The no objective testing rule (NOTR) is a decision aid designed to safely identify emergency department (ED) patients with chest pain who do not require objective testing for coronary artery disease.

OBJECTIVES: The objective was to validate the NOTR in a cohort of U.S. ED patients with acute chest pain and compare its performance to the HEART Pathway.

METHODS: A secondary analysis of 282 participants enrolled in the HEART Pathway randomized controlled trial was conducted. Each patient was classified as low risk or at risk by the NOTR. Sensitivity for major adverse cardiac events (MACE) at 30 days was calculated in the entire study population. NOTR and HEART Pathways were compared among patients randomized to the HEART Pathway in the parent trial using McNemar's test and the net reclassification improvement (NRI).

RESULTS: Major adverse cardiac events occurred in 22/282 (7.8%) participants, including no deaths, 16/282 (5.6%) with myocardial infarction (MI), and 6/282 (2.1%) with coronary revascularization without MI. NOTR was 100% (95% confidence interval [CI] = 84.6%-100%) sensitive for MACE and identified 78/282 patients (27.7%, 95% = CI 22.5-33.3%) as low risk. In the HEART Pathway arm (n = 141), both NOTR and HEART Pathway identified all patients with MACE as at risk. Compared to NOTR, the HEART Pathway was able to correctly reclassify 27 patients without MACE as low risk, yielding a NRI of 20.8% (95% CI = 11.3%-30.2%).

CONCLUSIONS: Within a U.S. cohort of ED patients with chest pain, the NOTR and HEART Pathway were 100% sensitive for MACE at 30 days. However, the HEART Pathway identified more patients suitable for early discharge than the NOTR.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Stopyra JP, Miller CD, Hiestand BC, et al. Validation of the No Objective Testing Rule and Comparison to the HEART Pathway. Acad Emerg Med. 2017. PMID: 28493646. doi:10.1111/acem.13221

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。